AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice.

[1]  Ta-Chiang Liu,et al.  Genetics and Pathogenesis of Inflammatory Bowel Disease. , 2016, Annual review of pathology.

[2]  K. Chowdhury,et al.  The aryl hydrocarbon receptor/microRNA-212/132 axis in T cells regulates IL-10 production to maintain intestinal homeostasis. , 2015, International immunology.

[3]  L. Chatenoud,et al.  Biotherapies targeting T and B cells: from immune suppression to immune tolerance. , 2015, Current opinion in pharmacology.

[4]  M. Neurath,et al.  Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo , 2015, Gut.

[5]  L. Notarangelo,et al.  Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. , 2015, Blood.

[6]  C. Clish,et al.  Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α , 2015, Nature Medicine.

[7]  C. Esser,et al.  The Aryl Hydrocarbon Receptor in Barrier Organ Physiology, Immunology, and Toxicology , 2015, Pharmacological Reviews.

[8]  Hua Yang,et al.  Aryl Hydrocarbon Receptor Activation Down-Regulates IL-7 and Reduces Inflammation in a Mouse Model of DSS-Induced Colitis , 2015, Digestive Diseases and Sciences.

[9]  Graham M Lord,et al.  Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease , 2015, Gut.

[10]  H. Weiner,et al.  Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation , 2014, Nature Medicine.

[11]  Chuan Wu,et al.  IL-21 induces IL-22 production in CD4+ T-cells , 2014, Nature Communications.

[12]  Y. Fujii‐Kuriyama,et al.  Identification of a probiotic bacteria‐derived activator of the aryl hydrocarbon receptor that inhibits colitis , 2014, Immunology and cell biology.

[13]  A. Palucka,et al.  Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.

[14]  F. Geissmann,et al.  TNF-α blockade induces IL-10 expression in human CD4+ T cells , 2014, Nature Communications.

[15]  Michael Hay,et al.  Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.

[16]  V. Kuchroo,et al.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39 , 2013, Nature Immunology.

[17]  Liang Zhou,et al.  Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. , 2013, Immunity.

[18]  M. Hattori,et al.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.

[19]  C. Mayne,et al.  Induced and Natural Regulatory T Cells in the Development of Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[20]  Junfeng Zhang,et al.  3,3'-Diindolylmethane alleviates oxazolone-induced colitis through Th2/Th17 suppression and Treg induction. , 2013, Molecular immunology.

[21]  A. Foussat,et al.  Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. , 2012, Gastroenterology.

[22]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[23]  J. Seavitt,et al.  Aiolos promotes TH17 differentiation by directly silencing Il2 expression , 2012, Nature Immunology.

[24]  Francisco J. Quintana,et al.  Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis , 2012, Proceedings of the National Academy of Sciences.

[25]  A. Rudensky,et al.  Regulatory T cells: mechanisms of differentiation and function. , 2012, Annual review of immunology.

[26]  L. Beaugerie.  Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? , 2011, Gut.

[27]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[28]  F. Carrat,et al.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.

[29]  H. Weiner,et al.  In Vivo Induction of Tr1 Cells via Mucosal Dendritic Cells and AHR Signaling , 2011, PloS one.

[30]  R. Price,et al.  Activation of Aryl Hydrocarbon Receptor (AhR) Leads to Reciprocal Epigenetic Regulation of FoxP3 and IL-17 Expression and Amelioration of Experimental Colitis , 2011, PloS one.

[31]  A. Rizzo,et al.  Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. , 2011, Gastroenterology.

[32]  C. Abraham,et al.  Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses , 2011, Proceedings of the National Academy of Sciences.

[33]  R. Arsenescu,et al.  Role of the xenobiotic receptor in inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[34]  D. Artis,et al.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22 , 2011, Nature Immunology.

[35]  Y. Fujii‐Kuriyama,et al.  A Role of the Aryl Hydrocarbon Receptor in Attenuation of Colitis , 2011, Digestive Diseases and Sciences.

[36]  D. Shepherd,et al.  Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn's disease. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  A. Nakao,et al.  Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis , 2011, Immunology and cell biology.

[38]  H. Weiner,et al.  An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis , 2010, Proceedings of the National Academy of Sciences.

[39]  H. Weiner,et al.  Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells , 2010, Nature Immunology.

[40]  A. Nakao,et al.  Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate‐induced colitis in mice , 2010, Immunology and cell biology.

[41]  D. Hafler,et al.  FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.

[42]  S. Eaton,et al.  High Expression of the Ectonucleotidase CD39 on T Cells from the Inflamed Site Identifies Two Distinct Populations, One Regulatory and One Memory T Cell Population , 2010, The Journal of Immunology.

[43]  Juan Ma,et al.  Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor. , 2010, Investigative ophthalmology & visual science.

[44]  A. Schäffer,et al.  Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. , 2009, The New England journal of medicine.

[45]  N. Kerkvliet,et al.  Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. , 2009, Immunotherapy.

[46]  M. Veldhoen,et al.  Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells , 2009, The Journal of experimental medicine.

[47]  F. Matsumura,et al.  Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. , 2008, Biochemical and biophysical research communications.

[48]  J. Buer,et al.  The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins , 2008, Nature.

[49]  P. Rossini,et al.  Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. , 2007, Blood.

[50]  E. Shevach,et al.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. , 2007, Blood.

[51]  V. Kuchroo,et al.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression , 2007, The Journal of experimental medicine.

[52]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[53]  L. Calabrese,et al.  The yin and yang of tumor necrosis factor inhibitors. , 2006, Cleveland Clinic journal of medicine.

[54]  P. Malfertheiner,et al.  Inhibition of RICK/Nuclear Factor-κB and p38 Signaling Attenuates the Inflammatory Response in a Murine Model of Crohn Disease* , 2005, Journal of Biological Chemistry.

[55]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[56]  T. Ley,et al.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death. , 2004, Immunity.

[57]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[58]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[59]  J. Garssen,et al.  Functional CD25– and CD25+ mucosal regulatory T cells are induced in gut‐draining lymphoid tissue within 48 h after oral antigen application , 2003, European journal of immunology.

[60]  Richard E Peterson,et al.  A ligand for the aryl hydrocarbon receptor isolated from lung , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  I. Fuss,et al.  Induction of TNBS colitis in mice. , 2002, Current protocols in immunology.

[62]  A. Persidis.  Autoimmune disease drug discovery , 1999, Nature Biotechnology.

[63]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[64]  G. Kollias,et al.  Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice , 1997, European journal of immunology.

[65]  A. Coutinho,et al.  Evidence for a Thymus‐Dependent Form of Tolerance that is Not Based on Elimination or Anergy of Reactive T cells , 1996, Immunological reviews.

[66]  M. Neurath,et al.  Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.

[67]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[68]  S. Sakaguchi,et al.  Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease , 1985, The Journal of experimental medicine.

[69]  J. Selkon,et al.  β-LACTAMASE-PRODUCING ANÆROBES , 1980, The Lancet.

[70]  F. Burnet,et al.  Immunological Function of Thymus and Bursa of Fabricius: Thymus Lesions in an Auto-immune Disease of Mice , 1962, Nature.

[71]  A. Szenberg,et al.  Immunological Function of Thymus and Bursa of Fabricius: Dissociation of Immunological Responsiveness in Fowls with a Hormonally Arrested Development of Lymphoid Tissues , 1962, Nature.

[72]  J. Miller,et al.  Immunological function of the thymus. , 1961, Lancet.

[73]  U. Kopylov,et al.  Optimizing anti-TNF treatments in inflammatory bowel disease. , 2014, Autoimmunity reviews.

[74]  A. Rudensky,et al.  TGFbeta signalling in control of T-cell-mediated self-reactivity. , 2007, Nature reviews. Immunology.

[75]  H. Ochs,et al.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.

[76]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.